Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

Journal of Clinical Oncology

Volumn 22, Issue 6, 2004, Pages 1110-1117

  Rudin, Charles M ^a   Kozloff, Mark ^a   Hoffman, Philip C ^a   Edelman, Martin J ^a   Karnauskas, Robyn ^a   Tomek, Ronald ^a   Szeto, Livia ^a   Vokes, Everett E ^a  

^a Ingalls Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; OBLIMERSEN; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; NUCLEOTIDE;

AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; HUMAN; LUNG SMALL CELL CANCER; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ADULT; AGED; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; FEMALE; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; SMALL CELL CARCINOMA; SURVIVAL RATE; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; THIONUCLEOTIDES; UNITED STATES;

EID: 1842562213     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.148     Document Type: Article

References (48)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Chute JP, Chen T, Feigal E, et al: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J Clin Oncol 17:1794-1801, 1999
3. Bork E, Ersboll J, Dombernowsky P, et al: Teniposide and etoposide in previously untreated small-cell lung cancer: A randomized study. J Clin Oncol 9:1627-1631, 1991
4. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
5. Clark PI, Slevin ML, Joel SP, et al: A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1435, 1994
6. Bunn PA Jr, Carney DN: Overview of chemotherapy for small cell lung cancer. Semin Oncol 24:57-69-57-74, 1997 (2 suppl 7)
7. Sandler AB: Current management of small cell lung cancer. Semin Oncol 24:463-476, 1997
8. Skarlos DV, Samantas E, Kosmidis P, et al: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5:601-607, 1994
9. Kosmidis PA, Samantas E, Fountzilas G, et al: Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 21:23-30, 1994
10. Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911, 1999
11. Rudin CM, Thompson CB: Apoptosis and disease: Regulation and clinical relevance of programmed cell death. Annu Rev Med 48:267-281, 1997
12. Reed JC: Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 9:451-173, 1995
13. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539-542, 1994
14. Lotem J, Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4:41-47, 1993
15. Campos L, Rouault JP, Sabido O, et al: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091-3096, 1993
16. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407-5411, 1992
17. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157, 1993
18. Walton MI, Whysong D, O'Connor PM, et al: Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53:1853-1861, 1993
19. Dole M, Nunez G, Merchant AK, et al: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253-3259, 1994
20. Fisher TC, Milner AE, Gregory CD, et al: Bcl-2 modulation of apoptosis induced by anti-cancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53:3321-3326, 1993
21. Minn AJ, Rudin CM, Boise LH, et al: Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910, 1995
22. Van JJ, Chen FF, Tsai YC, et al: Immuno-histochemical detection of Bcl-2 protein in small cell carcinomas. Oncology 53:6-11, 1996
23. Jiang SX, Sato Y, Kuwao S, et al: Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177:135-138, 1995
24. Ikegaki N, Katsumata M, Minna J, et al: Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54:6-8, 1994
25. Sartorius UA, Krammer PH: Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584-592, 2002
26. Zangemeister-Wittke U, Schenker T, Luedke GH, et al: Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78:1035-1042, 1998
27. Reed JC, Stein C, Subasinghe C, et al: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 50:6565-6570, 1990
28. Marcusson EG, Yacyshyn BR, Shanahan WR Jr, et al: Preclinical and clinical pharmacology of antisense oligonucleotides. Mol Biotechnol 12:1-11, 1999
29. Galderisi U, Cascino A, Giordano A: Antisense oligonucleotides as therapeutic agents. J Cell Physiol 181:251-257, 1999
30. Smith MR, Abubakr Y, Mohammad R, et al: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 2:207-212, 1995
31. Cotter FE, Johnson P, Hall P, et al: Anti-sense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3055, 1994
32. Jansen B, Schlagbauer-Wadl H, Brown BD, et al: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232-234, 1998
33. Leung S, Miyake H, Zellweger T, et al: Synergistic chemosensitization and inhibition of progression to androgen independence by anti-sense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int J Cancer 91:846-850, 2001
34. Yang D, Ling Y, Almazan M: Tumor regression of human breast carcinomas by combination therapy of anti-Bcl-2 antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 40:729, 1999 (abstr 4814)
35. Klasa RJ, Bally MB, Ng R, et al: Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6:2492-2500, 2000
36. Webb A, Cunningham D, Cotter F, et al: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349:1137-1141, 1997
37. Jansen B, Wacheck V, Heere-Ress E, et al: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728-1733, 2000
38. Rudin CM, Otterson GA, Mauer AM, et al: A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13: 539-545, 2002
39. Morris MJ, Tong WP, Cordon-Cardo C, et al: Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer. Clin Cancer Res 8:679-683, 2002
40. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
41. Wasan EK, Waterhouse D, Sivak O. et al: Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 anti-sense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241:57-64, 2002
42. Demidov LV, Kharkevitch G, Itri LM, et al: A pharmacokinetic study of oblimersen sodium (G3139) + dacarbazine (DTIC) in patients with metastatic melanoma. Proc Am Soc Clin Oncol 22:156, 2003 (abstr 623)
43. Raynaud FI, Orr RM, Goddard PM, et al: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281:420-427, 1997
44. Waters JS, Webb A, Cunningham D, et al: Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823, 2000
45. Marcucci G, Byrd JC, Dai G, et al: Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425-432, 2003
46. Chi KN, Cleave ME, Klasa R, et al: A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7:3920-3927, 2001
47. Klasa RJ, Gillum AM, Klem RE, et al: Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193-213, 2002
48. Dias N, Stein CA: Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 54:263-269, 2002